High-cost American medications — oncology, rare-disease, and biologic therapies — rarely fail on the science. They fail on the chain: sourcing at the origin, cold-chain integrity, and the documentation an import depends on.
The current has to be continuous
A tide does not stop, and neither can access. When a single partner owns the US-side chain end to end, the medication keeps moving toward the people who need it — no handoffs, no dropped links.
That is the work Tideon has built its nine years around.
The right medication, wherever you are — carried on a current that does not stop.
Have a specific therapy in mind? Tell us what you need.